Medicine, Health & Food

Medicine, Health & Food

EXPRESSION OF PROGRAMMED DEATH-LIGAND 1 (PD-L1) IMMUNOHISTOCHEMISTRY STAINING IN NASOPHARYNGEAL CARCINOMA AT RUMAH SAKIT UMUM PUSAT HAJI ADAM MALIK MEDAN 2018

Pages: 4  ,  Volume: 54  ,  Issue: 1 , June   2020
Received: 10 Jun 2020  ,  Published: 14 June 2020
Views: 43  ,  Download: 13

Authors

# Author Name
1 Epi Nuraini
2 Betty
3 M Nadjib Dahlan Lubis

Abstract

Background: Nasopharyngeal carcinoma (NPC) is carcinoma arising from nasopharyngeal mucosa that shows light microscopic of squamous differentiation. Data from GLOBOCAN (Global Burden of Cancer) 2018, nasopharyngeal carcinoma ranks fifth based on the incidence of new cases from all malignancies in Indonesia. The high mortality rate indicates that NPC management through surgery, radiotherapy, and chemotherapy have not been completely satisfactory. Recently, Programmed Death-Ligand 1 (PD-L1) inhibitor has developed which is an effective cancer immunotherapy. Abnormal expression of PD-L1 in various types of malignant tumors is associated with invasion, decreased T-lymphocyte infiltration, poor prognosis, and survival time. Objective: This study aimed to assess expression of Programmed Death-Ligand 1 (PD-L1) immunohistochemistry staining in nasopharyngeal carcinoma at Rumah Sakit Umum Pusat Haji Adam Malik Medan 2018. Material and Method: This study is descriptive and cross-sectional, which enrolled 50 PD-L1 stained slides of NPC biopsy and assessed by Histo-score. Expression of PD-L1 negative is 0-99, and positive is 100-300. Result: From 50 specimens in this study, we found that NPC patients were dominated by men (72%), with mean age 46,5±13,1 years-old. Positive expression of PD-L1 staining are 23 (46%) specimens, and negative expression of PD-L1 staining are 27 (54%) specimens. Conclusion: Expression of PD-L1 immunohistochemistry staining in this study were found fewer positive expressions compared to negative expressions.

Keywords

References

 

[1]     Petersson BF, Beli D, Lewis JS, Nadal A, Nicolai P, Wenig BM, et al. Nasopharyngeal carcinoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of head and neck tumours 4th ed. Lyon: IARC. 2017; pp.65–70

[2]     Chen Q, Hu W, Xiong H, Ying S, Ruan Y, Wu B, et al. Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy. Diagnostic Pathology. 2019; 14: pp.1–9

[3]     Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal Cancer. 2019; 144: pp.1941–1953

[4]     Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA. Cancer J. Clin. 2016; 66: pp.115–132

[5]     Lee AWM, Ma BBY, Ng WT, Chan ATC. Management of nasopharyngeal carcinoma: Current practice and future perspective. Journal of Clinical Oncology. 2015; 33: pp.3356–3364

[6]     Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010; 10: p.270

[7]     Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of Oncology. 2014; 25: pp.1935–1940

[8]     Salehiniya H, Mohammadian M, Hafshejani AH, Mahdavifar N. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. World Cancer Research Journal. 2018

[9]     Farhat, Asnir RA, Yudhistira A, Susilo RR, Daulay ER, Chrestella J. Correlation of TNF-α expression to clinical stadium in nasopharyngeal carcinoma (NPC). Stem Cell Oncology. 2018

[10]  Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Herman B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in indonesia: Epidemiology, incidence, signs, and symptoms at presentation. Chinese Journal of Cancer. 2012; 31: pp.185–196

[11]  Munir D. Beberapa aspek karsinoma nasofaring pada suku batak di Medan dan sekitarnya. Majalah Kedokteran Nusantara Volume 39. No.3. 2006

[12]  Li Y, Ding J, Liao L, Zhang Z, Liao S, Wu Y, et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Molecular and Clinical Oncology. 2017; 7: pp.378–382

[13]  Lee VHF, Lo AWI, Leung C, Shek W, Kwong DLW, Lam K, et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. Plos One. 2016

[14]  Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy. 2016; 9: pp.5023-5039

[15]  Deng L, Liang H, Burnette B. Irradiation and anti PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124: pp.687-695